Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Aktis Oncology, Inc.NASDAQ: AKTS
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities of $5.05M in Q1 FY2026
Q1 FY2026 other current liabilities was $5.05M. Over 3 fiscal years it compounded at +56.4% a year.
Context
- Other current liabilities amounted to 0.9% of total assets at the end of Q1 FY2026.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 4.56M USD
- Year-over-year change
- +48.0%
- 3-year CAGR
- +56.4%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.56M | +48.0% |
| FY2024 | 2024-12-31 | 3.08M | +51.7% |
| FY2023 | 2023-12-31 | 2.03M | +70.3% |
| FY2022 | 2022-12-31 | 1.19M | — |
Other Current Liabilities vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 other current liabilities of $5.05M is the 5th highest of the 6 companies compared; the peer median is $18.45M.
- Other current liabilities amounts to 0.9% of total assets for AKTS, versus a peer median of 8.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $207.39M | +4356.1% | +188.5% | 19.3% | |
| Sep 2026 | $40.97M | +359.6% | +97.7% | 8.1% | |
| Mar 2026 | $18.45M | — | -8.5% | 8.5% | |
| Mar 2026 | $9.58M | -56.5% | +8.5% | 1.5% | |
| Mar 2026 | $5.05M | — | +56.4% | 0.9% | |
| Mar 2026 | $2.97M | -6.6% | +27.3% | 2.2% | |
| Peer median (excluding AKTS) | $18.45M | +176.5% | +27.3% | 8.1% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.